CY1113705T1 - Μεθοδοι για τη θεραπεια αιμορραγικων διαταραχων με τη χρηση θειωμενων πολυσακχαριτων - Google Patents
Μεθοδοι για τη θεραπεια αιμορραγικων διαταραχων με τη χρηση θειωμενων πολυσακχαριτωνInfo
- Publication number
- CY1113705T1 CY1113705T1 CY20131100157T CY131100157T CY1113705T1 CY 1113705 T1 CY1113705 T1 CY 1113705T1 CY 20131100157 T CY20131100157 T CY 20131100157T CY 131100157 T CY131100157 T CY 131100157T CY 1113705 T1 CY1113705 T1 CY 1113705T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disorders
- treatment
- methods
- nasps
- polysakharites
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Περιγράφονταν μέθοδοι για θεραπεία αιμορραγικών διαταραχών με χρήση μη-θειωμένου πολυσακχαρίτη αντιπηκτικού (NASPs). Τα NASPs μπορούν να χορηγηθούν ως παράγοντες για την πήξη. Τα NASPs μπορούν να χορηγηθούν ως μεμονωμένοι παράγοντες ή σε συνδυασμό με άλλο, ή με άλλους αιμοστατικούς παράγοντες. Ειδικότερα, περιγράφεται η χρήση των NASPs στη θεραπεία αιμορραγικών διαταραχών, συμπεριλαμβανομένων των συγγενών διαταραχών πήξης, επίκτητων διαταραχών πήξης, και αιμορραγικών συνθηκών λόγω τραύματος.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57484504P | 2004-05-27 | 2004-05-27 | |
EP05765950A EP1748781B1 (en) | 2004-05-27 | 2005-05-27 | Methods for treating bleeding disorders using sulfated polysaccharides |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113705T1 true CY1113705T1 (el) | 2016-06-22 |
Family
ID=35462725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100157T CY1113705T1 (el) | 2004-05-27 | 2013-02-21 | Μεθοδοι για τη θεραπεια αιμορραγικων διαταραχων με τη χρηση θειωμενων πολυσακχαριτων |
Country Status (16)
Country | Link |
---|---|
US (4) | US7767654B2 (el) |
EP (2) | EP2165711B1 (el) |
JP (2) | JP5232470B2 (el) |
CN (2) | CN1984664B (el) |
AU (1) | AU2005249465B2 (el) |
BR (1) | BRPI0511603A (el) |
CA (1) | CA2567495C (el) |
CY (1) | CY1113705T1 (el) |
DK (1) | DK1748781T3 (el) |
ES (2) | ES2399277T3 (el) |
HK (2) | HK1103624A1 (el) |
PL (1) | PL1748781T3 (el) |
PT (1) | PT1748781E (el) |
RU (1) | RU2347574C2 (el) |
SI (1) | SI1748781T1 (el) |
WO (1) | WO2005117912A1 (el) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
ES2399277T3 (es) * | 2004-05-27 | 2013-03-27 | Baxter International Inc. | Procedimiento de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados |
US20080107678A1 (en) * | 2006-04-27 | 2008-05-08 | Johnson Kirk W | Method for treating thrombotic disorders using sulfated polysaccharides |
WO2008103234A1 (en) * | 2007-02-23 | 2008-08-28 | Baxter, International Inc. | Process methods for fucoidan purification from seaweed extracts |
US9956272B2 (en) * | 2007-05-30 | 2018-05-01 | Bio Products Laboratory Limited | Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same |
WO2009061697A1 (en) | 2007-11-09 | 2009-05-14 | The Board Of Trustees Of The University Of Illinois | Anticoagulant antagonist and hemophilia procoagulant |
US8546096B2 (en) * | 2008-08-22 | 2013-10-01 | Baxter International Inc. | Method for identifying a non-anticoagulant sulfated polysaccharide which enhances blood coagulation dependence on FXI |
CN102307600B (zh) * | 2008-12-11 | 2015-11-25 | 巴克斯特国际公司 | 以纤维蛋白原和硫酸化多糖为基础的制剂 |
US8466108B2 (en) | 2008-12-19 | 2013-06-18 | Baxter International Inc. | TFPI inhibitors and methods of use |
AU2011205271B2 (en) * | 2010-01-14 | 2014-01-30 | Baxalta GmbH | Methods and compositions for treating bleeding disorders |
BR112012023559A2 (pt) | 2010-03-19 | 2017-10-17 | Baxter Healthcare Sa | inibidores tfpi e métodos de uso |
EP2947148B1 (en) * | 2010-04-20 | 2017-06-07 | Octapharma AG | New stabilizing agent for pharmaceutical proteins |
JP6000259B2 (ja) | 2010-10-06 | 2016-09-28 | メドイミューン・リミテッドMedImmune Limited | 止血障害治療用第ii因子およびフィブリノーゲン |
CA2838793C (en) * | 2011-07-19 | 2019-08-06 | Baxter International Inc. | Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
JP6138829B2 (ja) * | 2012-01-30 | 2017-05-31 | バクスアルタ ゲーエムベーハー | 非抗凝固性の硫酸化またはスルホン酸化合成ポリマー |
JP6228137B2 (ja) * | 2012-01-30 | 2017-11-08 | バクスアルタ ゲーエムベーハー | 非抗凝固性の硫酸化またはスルホン酸化多糖 |
KR102263685B1 (ko) | 2012-03-21 | 2021-06-11 | 다케다 야쿠힌 고교 가부시키가이샤 | Tfpi 저해제 및 사용 방법 |
RU2472495C1 (ru) * | 2012-05-05 | 2013-01-20 | Илья Николаевич Медведев | Способ нормализации уровня альфа2-антиплазмина у свиноматок с бронхитом |
EP2662083A1 (en) | 2012-05-08 | 2013-11-13 | CSL Behring GmbH | Sugar compositions for treating hemophilia a and/or von willebrand disease |
EP2885642B1 (en) * | 2012-08-14 | 2019-05-15 | Baxalta GmbH | Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides |
CN103610684B (zh) * | 2013-11-07 | 2016-04-06 | 苏州大学 | 糖类在制备治疗血小板数量相关疾病的药物中的应用 |
JPWO2018043667A1 (ja) | 2016-08-31 | 2018-08-30 | 王子ホールディングス株式会社 | 酸性キシロオリゴ糖の製造方法及び酸性キシロオリゴ糖 |
JP6225321B1 (ja) * | 2016-08-31 | 2017-11-08 | 王子ホールディングス株式会社 | ポリ硫酸ペントサンの製造方法 |
JP6281659B1 (ja) | 2017-02-28 | 2018-02-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン、医薬組成物及び抗凝固剤 |
KR20240023711A (ko) | 2017-05-31 | 2024-02-22 | 오지 홀딩스 가부시키가이샤 | 보습 외용제 |
EP3683242A4 (en) | 2017-09-12 | 2021-11-03 | Oji Holdings Corporation | PENTOSAN POLYSULFATE AND METHOD FOR MANUFACTURING PENTOSAN POLYSULFATE |
MX2020006605A (es) | 2017-12-20 | 2020-09-10 | Oji Holdings Corp | Polisulfato de pentosano y medicamento que contiene polisulfato de pentosano. |
CN108822231A (zh) * | 2018-06-29 | 2018-11-16 | 桂林理工大学 | 一种具有提高抗氧化活性的果胶多糖硫酸化修饰产物及其制备方法 |
SE1950885A1 (en) * | 2019-07-11 | 2021-01-12 | Faelker Knut | Treatment of patients undergoing antiplatelet medication experiencing acute bleeding complications during / after surgery |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL79254A0 (en) * | 1986-06-26 | 1986-09-30 | Hadassah Med Org | Compositions for preventing graft rejection |
IL85145A (en) * | 1987-01-23 | 1994-08-26 | Univ Australian | Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity |
ATE121139T1 (de) * | 1990-11-05 | 1995-04-15 | Baxter Diagnostics Inc | Verfahren zur bestimmung der konzentration von antikoagulantien. |
JP3714426B2 (ja) | 1994-02-01 | 2005-11-09 | 株式会社糖鎖工学研究所 | フコイダンオリゴ糖組成物含有癌転移抑制剤 |
DE69637747D1 (de) * | 1995-04-28 | 2008-12-24 | Res Inst For Glycotechnology H | Zuckerverbindungen |
FR2754183A1 (fr) * | 1996-10-08 | 1998-04-10 | Lefebvre Jean Marie | Composition visqueuse hemostatique, notamment a l'etat de gel |
EP0977995B1 (de) * | 1997-04-25 | 2005-03-02 | Pentapharm AG | Verfahren zum funktionellen nachweis von störungen im protein c-system |
UA65587C2 (en) | 1997-10-09 | 2004-04-15 | Baker Norton Pharma | Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus |
JP4261071B2 (ja) * | 1999-04-15 | 2009-04-30 | タカラバイオ株式会社 | 治療剤 |
AU2001244602A1 (en) * | 2000-03-30 | 2001-10-15 | Ajinomoto Co. Inc. | Drugs retained in target tissue over long time |
US20030203845A1 (en) * | 2001-02-05 | 2003-10-30 | Knudsen Jens Bjerre | Combined use of factor VII polypeptides and factor IX polypeptides |
KR20030088430A (ko) * | 2001-02-05 | 2003-11-19 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ⅶ 폴리펩티드 및 인자 ⅸ 폴리펩티드의 조합 사용 |
DE60202427T2 (de) * | 2001-10-24 | 2005-12-29 | Takara Bio Inc., Otsu | Sulfatiertes Fucan-Oligosaccharid |
JP3941036B2 (ja) * | 2001-12-07 | 2007-07-04 | サンスター株式会社 | 経口投与のためのリポソーム組成物 |
DE10309368A1 (de) * | 2002-08-06 | 2004-02-26 | Aventis Behring Gmbh Intellectual Property/Legal | Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase |
IL152030A0 (en) * | 2002-09-30 | 2003-05-29 | Nvr Labs Ltd Neural & Vascular | Cohesive biopolymers comprising sulfated polysaccharides and fibrillar proteins and use thereof for tissue repair |
JP2004144580A (ja) * | 2002-10-23 | 2004-05-20 | Japan Clinical Laboratories Inc | 血液凝固検査方法 |
US20050033029A1 (en) * | 2003-06-30 | 2005-02-10 | Jin Lu | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
ES2399277T3 (es) * | 2004-05-27 | 2013-03-27 | Baxter International Inc. | Procedimiento de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados |
US20080107678A1 (en) * | 2006-04-27 | 2008-05-08 | Johnson Kirk W | Method for treating thrombotic disorders using sulfated polysaccharides |
-
2005
- 2005-05-27 ES ES05765950T patent/ES2399277T3/es active Active
- 2005-05-27 EP EP09180857.6A patent/EP2165711B1/en active Active
- 2005-05-27 EP EP05765950A patent/EP1748781B1/en active Active
- 2005-05-27 US US11/140,504 patent/US7767654B2/en active Active
- 2005-05-27 PT PT57659500T patent/PT1748781E/pt unknown
- 2005-05-27 WO PCT/US2005/018669 patent/WO2005117912A1/en active Application Filing
- 2005-05-27 DK DK05765950.0T patent/DK1748781T3/da active
- 2005-05-27 CN CN2005800236583A patent/CN1984664B/zh active Active
- 2005-05-27 CN CN2013101636132A patent/CN103251647A/zh active Pending
- 2005-05-27 SI SI200531664T patent/SI1748781T1/sl unknown
- 2005-05-27 JP JP2007515373A patent/JP5232470B2/ja active Active
- 2005-05-27 BR BRPI0511603-1A patent/BRPI0511603A/pt not_active IP Right Cessation
- 2005-05-27 RU RU2006146801/15A patent/RU2347574C2/ru not_active IP Right Cessation
- 2005-05-27 ES ES09180857.6T patent/ES2482105T3/es active Active
- 2005-05-27 PL PL05765950T patent/PL1748781T3/pl unknown
- 2005-05-27 AU AU2005249465A patent/AU2005249465B2/en active Active
- 2005-05-27 CA CA2567495A patent/CA2567495C/en active Active
-
2007
- 2007-07-20 HK HK07107845.5A patent/HK1103624A1/xx unknown
-
2009
- 2009-04-13 US US12/386,026 patent/US7829549B2/en active Active
-
2010
- 2010-09-16 HK HK10108794.9A patent/HK1142276A1/xx unknown
- 2010-09-29 US US12/893,798 patent/US8859526B2/en active Active
-
2011
- 2011-05-19 US US13/111,746 patent/US8771973B2/en active Active
- 2011-12-05 JP JP2011266214A patent/JP2012046551A/ja active Pending
-
2013
- 2013-02-21 CY CY20131100157T patent/CY1113705T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113705T1 (el) | Μεθοδοι για τη θεραπεια αιμορραγικων διαταραχων με τη χρηση θειωμενων πολυσακχαριτων | |
CY1115117T1 (el) | Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα | |
DE60333937D1 (de) | Substituierte quinazolinone verbindungen | |
ATE505488T1 (de) | Modulator von coagulationskaskaden und fibrinolytischen kaskaden | |
BRPI0518565A2 (pt) | composiÇÕes cardiovasculares | |
MX2010003095A (es) | Antidotos para inhibidores del factor xa y metodos para usar los mismos. | |
DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
ATE551076T1 (de) | Hämostyptikum zur topischen und inneren anwendung | |
WO2007098114A3 (en) | Clotting and healing compositions containing keratin biomaterials | |
NO20091655L (no) | Substituerte dihydropyrazoloner for behandling av kardiovaskulaere og hematologiske sykdommer | |
DE502004001289D1 (de) | PYRROLIDIN-1,2-DICARBONSÄURE-1-i(4-ETHINYL-PHENYL)-AMIDö-2-i(PHENYL)-AMIDö DERIVATE ALS INHIBITOREN DER KOAGULATIONSFAKTOREN XA UND VIIA ZUR BEHANDLUNG VON THROMBOSEN | |
BR0306993A (pt) | Polìmero de polialquilenoglicol ativado; composição farmacêutica; método para tratar um paciente que tem uma infecção viral suscetìvel; e método para tratar um paciente suspeito de ter infecção por hepatite c | |
AR045016A1 (es) | Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades. | |
RU2006143838A (ru) | Применение дипиридамола для лечения устойчивости к ингибиторам тромбоцитов | |
EA201170484A1 (ru) | Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950 | |
Scerrino et al. | The use of haemostatic agents in thyroid surgery: efficacy and further advantages. Collagen-Fibrinogen-Thrombin Patch (CFTP) versus Cellulose Gauze | |
Goelder et al. | Endoscopic hemostasis state of the art-Nonvariceal bleeding | |
RU2010102090A (ru) | Композиции для антифибринолитического лечения | |
ATE395067T1 (de) | Verwendung von sulfatierten glykosaminoglykanen zur herbeiführung von effektiven wehen bei frauen | |
EA200602002A1 (ru) | Применение спинозинов для заживления ран | |
HUP0401188A2 (hu) | Hiperelágazásos amilopektin sebészeti, gyógyító vagy diagnosztikai eljárásokban emlősöknél való alkalmazásra, különösen plazmatérfogat-növelőként | |
AR046969A1 (es) | Composicion enteral para la cicatrizacion de heridas | |
WO2007027178A3 (en) | Lyophilized platelet rich plasma for the use in wound healing and bone or tissue grafts or repair | |
RU2284765C1 (ru) | Способ лечения флегмоны дна полости рта | |
Kumbasar et al. | The effect of fibrin sealant spraying on prolonged air leak after pulmonary resections: a single center experience |